American Well Corp (AMWL): Results of Operations and Financial Condition
American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on the updated revenue and adjusted EBITDA guidance ranges, plus the stated objective of positive operating cash flow in Q4 2026.
Market read
The filing provides fresh, numeric guidance updates (2026 and Q3) and Q2 operating metrics (revenue, gross margin, EBITDA trend) that can drive near-term positioning.
What to watch
The filing emphasizes DHA contractor intent and cash-flow timing for Q4, but it also flags risks around client transitions, telehealth demand volatility, and cybersecurity/privacy compliance.
Background
This is an SEC 8-K with Exhibit 99.1 reporting Amwell’s Q2 2026 results and updated financial outlook, including Q3 2026 ranges.
Ticker impact
Amwell reported Q2 2026 revenue of $52.0M, gross margin of 53%, and raised the low end of 2026 revenue and adjusted EBITDA guidance.
Near-term bias upward on guidance credibility, with volatility risk given continued GAAP net losses and non-GAAP framing.
The filing includes specific Q2 results and updated 2026 and Q3 ranges, which are actionable for positioning. However, the company does not reconcile forward-looking adjusted EBITDA to GAAP, and GAAP net loss persists, limiting conviction.
Market effects
Reinforces a potential inflection narrative for telehealth/SaaS healthcare platforms via subscription growth and improving EBITDA trajectory.
No specific regional spillover disclosed beyond US healthcare contracting.
Limited, as the disclosed guidance and DHA relationship are US-focused.
Counterpoint
Non-GAAP adjusted EBITDA remains negative and GAAP net loss is still sizable, so the guidance raise may not translate into durable profitability.
Key entities
- issuerAmerican Well Corp
NYSE-listed SaaS-based healthcare platform provider reporting Q2 2026 results and updated guidance.
- customerDefense Health Agency (DHA)
Referenced as intending to make Amwell a prime contractor, supporting the platform endorsement narrative.
